Randomised clinical trial to test the phenolization in sacrococcygeal pilonidal disease

Identifier:  imarina:9291701

Handle: https://hdl.handle.net/20.500.11797/imarina9291701

Authors:  Elvira Lopez, Jordi; Escuder Perez, Jorge; Sales Mallafre, Ricard; Feliu Villaro, Francsec; Caro Tarrago, Aleidis; Espina Perez, Beatriz; Ferreres Serafini, Joan; Jorba Martin, Rosa

Abstract:
To test the efficacy and safety of phenolization in uncomplicated Sacrococcygeal pilonidal disease (SPD) the phenolization in uncomplicated SPD is feasible and secure in selected patients in observational studies. The greatest benefits are obtained to reduce the length of sick leave (LSL) and complications. Single-center randomised controlled clinical trial. Patients were recruited at University Hospital of Tarragona Joan XXIII of Spain. Patients were randomised into two treatment groups. All patients with uncomplicated sacrococcygeal disease, localised in the midline and with only 1 fistulous orifice. The patients were randomly assigned to the phenolization group (PhG) or conventional-surgery group (CsG). Both groups were managed without admission. The main endpoint was the recurrence of sacrococcygeal disease. Secondary endpoints included time of sick leave, complications, and readmission. 124 patients were included in the study. No disease recurrence was observed in either group. Clinical follow-up was carried out with a mean of 493.8 days (SD 6.59). The LSL was shorter in the PhG (mean 19.63 days, SD 28.15) than in the CSG (43.95 days, SD 38.60). The LSL reduction was −24.31 days (P.002). The phenolization in selected SPD is a safe and feasible procedure in selected patients. This approach could become the standard of care for patients with selected Sacrococcygeal pilonidal.